42 related articles for article (PubMed ID: 8204881)
1. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation.
Guerrero JA; Kyei M; Russell S; Liu J; Gartner TK; Storrie B; Ware J
Blood; 2009 Dec; 114(27):5541-6. PubMed ID: 19808696
[TBL] [Abstract][Full Text] [Related]
2. In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma-derived von Willebrand factor products.
Turecek PL; Ilk R; Gritsch H
Haemophilia; 2024 Jan; 30(1):151-160. PubMed ID: 37926687
[TBL] [Abstract][Full Text] [Related]
3. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.
Flood VH; Friedman KD; Gill JC; Morateck PA; Wren JS; Scott JP; Montgomery RR
J Thromb Haemost; 2009 Nov; 7(11):1832-9. PubMed ID: 19694940
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
Mannucci PM; Kempton C; Millar C; Romond E; Shapiro A; Birschmann I; Ragni MV; Gill JC; Yee TT; Klamroth R; Wong WY; Chapman M; Engl W; Turecek PL; Suiter TM; Ewenstein BM;
Blood; 2013 Aug; 122(5):648-57. PubMed ID: 23777763
[TBL] [Abstract][Full Text] [Related]
5. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.
Stockschlaeder M; Schneppenheim R; Budde U
Blood Coagul Fibrinolysis; 2014 Apr; 25(3):206-16. PubMed ID: 24448155
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the physiological significance of botrocetin/ von Willebrand factor in vitro signaling.
Liu J; Joglekar M; Ware J; Fitzgerald ME; Lowell CA; Berndt MC; Gartner TK
J Thromb Haemost; 2008 Nov; 6(11):1915-22. PubMed ID: 18752568
[TBL] [Abstract][Full Text] [Related]
7. Hemostatic potential of recombinant von Willebrand factor and standard or pegylated extended half-life recombinant factor VIII on thrombus formation under high shear flow.
Yaoi H; Shida Y; Ogiwara K; Nogami K
Thromb J; 2023 Dec; 21(1):122. PubMed ID: 38066509
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States.
Waldron C; Ito S; Wang D; Allen C; Viswanathan G; Bona RD; Cuker A; Goshua G
Blood; 2024 May; 143(22):2332-2335. PubMed ID: 38635764
[TBL] [Abstract][Full Text] [Related]
9. Nanobody activator improves sensitivity of the von Willebrand factor activity assay to multimer size.
Liang Q; Parker ET; Dean G; Karpen MS; Wu Y; Wang X; Di Paola J; Maier CL; Meeks SL; Lollar P; Sidonio RF; Li R
J Thromb Haemost; 2024 May; ():. PubMed ID: 38704122
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand Factor Multimers and the Relaxation Response: A One-Year Study.
Dal Lin C; Acquasaliente L; Iliceto S; De Filippis V; Vitiello G; Tona F
Entropy (Basel); 2021 Apr; 23(4):. PubMed ID: 33920144
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms by which von Willebrand disease mutations destabilize the A2 domain.
Xu AJ; Springer TA
J Biol Chem; 2013 Mar; 288(9):6317-24. PubMed ID: 23322777
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of type 2A von Willebrand disease investigated by molecular dynamics simulations and experiments.
Interlandi G; Ling M; Tu AY; Chung DW; Thomas WE
PLoS One; 2012; 7(10):e45207. PubMed ID: 23110044
[TBL] [Abstract][Full Text] [Related]
13. Functional property of von Willebrand factor under flowing blood.
Sugimoto M; Miyata S
Int J Hematol; 2002 Jan; 75(1):19-24. PubMed ID: 11843285
[TBL] [Abstract][Full Text] [Related]
14. Influence of mutations and size of multimers in type II von Willebrand disease upon the function of von Willebrand factor.
Christophe O; Ribba AS; Baruch D; Obert B; Rouault C; Niinomi K; Piétu G; Meyer D; Girma JP
Blood; 1994 Jun; 83(12):3553-61. PubMed ID: 8204881
[TBL] [Abstract][Full Text] [Related]
15. Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin.
Randi AM; Jorieux S; Tuley EA; Mazurier C; Sadler JE
J Biol Chem; 1992 Oct; 267(29):21187-92. PubMed ID: 1400429
[TBL] [Abstract][Full Text] [Related]
16. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
[TBL] [Abstract][Full Text] [Related]
17. Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.
Ribba AS; Voorberg J; Meyer D; Pannekoek H; Pietu G
J Biol Chem; 1992 Nov; 267(32):23209-15. PubMed ID: 1429668
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of von Willebrand disease.
Mazurier C; Ribba AS; Gaucher C; Meyer D
Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetics of type 2 von Willebrand disease.
Fressinaud E; Mazurier C; Meyer D
Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
